RS65255B1 - Lek za lečenje infektivnih bolesti - Google Patents
Lek za lečenje infektivnih bolestiInfo
- Publication number
- RS65255B1 RS65255B1 RS20240275A RSP20240275A RS65255B1 RS 65255 B1 RS65255 B1 RS 65255B1 RS 20240275 A RS20240275 A RS 20240275A RS P20240275 A RSP20240275 A RS P20240275A RS 65255 B1 RS65255 B1 RS 65255B1
- Authority
- RS
- Serbia
- Prior art keywords
- medicament
- infectious diseases
- treating infectious
- treating
- diseases
- Prior art date
Links
- 208000035473 Communicable disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2019127186A RU2778522C2 (ru) | 2019-08-29 | Лекарственное средство для лечения инфекционных заболеваний | |
RU2019127185A RU2778521C2 (ru) | 2019-08-29 | Лекарственное средство для лечения бактериальных инфекций | |
PCT/RU2020/050193 WO2021040570A1 (en) | 2019-08-29 | 2020-08-19 | Medicament and method for treating infectious diseases |
EP20800353.3A EP4021505B1 (en) | 2019-08-29 | 2020-08-19 | Medicament for treating infectious diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
RS65255B1 true RS65255B1 (sr) | 2024-03-29 |
Family
ID=73040208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20240275A RS65255B1 (sr) | 2019-08-29 | 2020-08-19 | Lek za lečenje infektivnih bolesti |
Country Status (16)
Country | Link |
---|---|
US (1) | US20220213197A1 (sr) |
EP (1) | EP4021505B1 (sr) |
JP (1) | JP2022545178A (sr) |
CN (1) | CN114375200A (sr) |
BR (1) | BR112022001472A2 (sr) |
DK (1) | DK4021505T3 (sr) |
ES (1) | ES2973183T3 (sr) |
FI (1) | FI4021505T3 (sr) |
HR (1) | HRP20240331T1 (sr) |
HU (1) | HUE065591T2 (sr) |
MX (1) | MX2022000536A (sr) |
PL (1) | PL4021505T3 (sr) |
PT (1) | PT4021505T (sr) |
RS (1) | RS65255B1 (sr) |
SI (1) | SI4021505T1 (sr) |
WO (1) | WO2021040570A1 (sr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117771379A (zh) * | 2023-10-25 | 2024-03-29 | 珠海泰诺麦博制药股份有限公司 | 特异性结合金黄色葡萄球菌Hla毒素的全人源抗体与抗生素的组合 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
RU2205025C1 (ru) | 2001-12-26 | 2003-05-27 | Гольдберг Евгений Данилович | Способ коррекции иммунного ответа и лекарственное средство |
RU2309732C1 (ru) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
RU2363470C1 (ru) | 2007-12-26 | 2009-08-10 | Государственное образовательное учреждение высшего профессионального образования Самарский государственный медицинский университет | Способ преодоления лекарственной устойчивости бактерий и грибов |
RU2521392C2 (ru) | 2010-08-06 | 2014-06-27 | Олег Ильич Эпштейн | Комплексное лекарственное средство для лечения вирусных заболеваний и способ лечения вирусных заболеваний |
RU2500422C2 (ru) | 2010-08-06 | 2013-12-10 | Олег Ильич Эпштейн | Комплексное лекарственное средство для лечения вирусных инфекций и способ лечения вирусных инфекций |
SG10201403870XA (en) * | 2010-08-06 | 2014-08-28 | Oleg Iliich Epshtein | Combination Pharmaceutical Composition And Methods Of Treating And Preventing The Infectious Diseases |
RU2655808C2 (ru) | 2016-10-11 | 2018-05-29 | Закрытое Акционерное Общество "Биологические Исследования И Системы" (Зао "Бис") | Фармацевтическая комбинированная композиция для местного и наружного применения на основе бактериолитического и протеолитического комплекса ферментов |
-
2020
- 2020-08-19 HU HUE20800353A patent/HUE065591T2/hu unknown
- 2020-08-19 JP JP2022506768A patent/JP2022545178A/ja active Pending
- 2020-08-19 ES ES20800353T patent/ES2973183T3/es active Active
- 2020-08-19 MX MX2022000536A patent/MX2022000536A/es unknown
- 2020-08-19 RS RS20240275A patent/RS65255B1/sr unknown
- 2020-08-19 EP EP20800353.3A patent/EP4021505B1/en active Active
- 2020-08-19 DK DK20800353.3T patent/DK4021505T3/da active
- 2020-08-19 FI FIEP20800353.3T patent/FI4021505T3/fi active
- 2020-08-19 PT PT208003533T patent/PT4021505T/pt unknown
- 2020-08-19 WO PCT/RU2020/050193 patent/WO2021040570A1/en active Application Filing
- 2020-08-19 HR HRP20240331TT patent/HRP20240331T1/hr unknown
- 2020-08-19 BR BR112022001472A patent/BR112022001472A2/pt unknown
- 2020-08-19 SI SI202030365T patent/SI4021505T1/sl unknown
- 2020-08-19 CN CN202080060725.3A patent/CN114375200A/zh active Pending
- 2020-08-19 US US17/608,270 patent/US20220213197A1/en active Pending
- 2020-08-19 PL PL20800353.3T patent/PL4021505T3/pl unknown
Also Published As
Publication number | Publication date |
---|---|
US20220213197A1 (en) | 2022-07-07 |
JP2022545178A (ja) | 2022-10-26 |
CN114375200A (zh) | 2022-04-19 |
ES2973183T3 (es) | 2024-06-18 |
MX2022000536A (es) | 2022-02-10 |
EP4021505B1 (en) | 2023-12-13 |
SI4021505T1 (sl) | 2024-03-29 |
PL4021505T3 (pl) | 2024-06-24 |
FI4021505T3 (fi) | 2024-03-01 |
WO2021040570A1 (en) | 2021-03-04 |
DK4021505T3 (da) | 2024-02-12 |
HUE065591T2 (hu) | 2024-06-28 |
PT4021505T (pt) | 2024-03-11 |
EP4021505A1 (en) | 2022-07-06 |
BR112022001472A2 (pt) | 2022-03-22 |
HRP20240331T1 (hr) | 2024-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277190A (en) | Methods of treating HPV-related diseases | |
HK1258588A1 (zh) | 用於治療眼科疾病的化合物和製劑 | |
IL277333A (en) | Methods for treating eye diseases | |
SG11202012339WA (en) | Co-receptor systems for treating infectious diseases | |
IL288958A (en) | Exosomes for the treatment of diseases | |
IL290770A (en) | Compounds and methods for treating oxalate-related diseases | |
IL288793A (en) | Compounds for the treatment of respiratory diseases | |
EP3375443A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISEASES | |
EP3634583A4 (en) | LONG-ACTION IMPLANT FOR THE TREATMENT OF INFECTIOUS DISEASES | |
EP4061167C0 (en) | PROTECTIVE HOOD FOR MEDICAL USE | |
HUE065591T2 (hu) | Gyógyszer fertõzõ betegségek kezelésére | |
IL289436A (en) | Methods for treating eye diseases | |
IL286680A (en) | A drug to treat cancer | |
IL279078A (en) | Combination therapy for the treatment of hepatitis B viral infection | |
EP3958754C0 (fr) | Dispositif pour le traitement de la maladie hemorroïdaire | |
GB201914296D0 (en) | Treatment | |
GB201908885D0 (en) | Therapeutic compounds | |
GB201917691D0 (en) | Compounds for treating respiratory disease | |
GB201908451D0 (en) | Compounds for treating respiratory disease | |
GB201908453D0 (en) | Compounds for treating respiratory disease | |
EP3774729A4 (en) | TREATMENT OF INFECTIOUS DISEASES | |
GB201903547D0 (en) | Treatment for autoimmune diseases | |
GB201911728D0 (en) | Bacterial composistions for the treatment of disease | |
EP4058063A4 (en) | METHODS OF TREATMENT OF DISEASES | |
EP3743075A4 (en) | COMPOUNDS FOR TREATMENT OF ILK-MEDIATED DISEASES |